Charles River Laboratories International, Inc. is a drug development company. It provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and academic institutions around the globe accelerate their research and drug development efforts. Its Research Models and Services segment includes three businesses that provide foundational tools that enable its clients to discover new molecules: Research Models, Research Model Services, and Cell Solutions. Its Discovery and Safety Assessment segment provides regulated and non-regulated DSA services to support the research, development, and regulatory-required safety testing of potential new drugs, including therapeutic discovery and optimization plus in vitro and in vivo studies, laboratory support services, and strategic non-clinical consulting and program management to support product development. Its Manufacturing Solutions segment includes Microbial Solutions and Biologics Solutions.
āļŠāļąāļāļĨāļąāļāļĐāļāđāļĒāđāļāļāļāļāļŦāļļāđāļCRL
āļāļ·āđāļāļāļĢāļīāļĐāļąāļCharles River Laboratories International Inc
āļ§āļąāļāļāļĩāđāđāļŠāļāļāļāļēāļĒāļāļĢāļąāđāļāđāļĢāļJun 23, 2000
āļāļĩāļāļĩāđāļFoster (James C)
āļāļģāļāļ§āļāļāļāļąāļāļāļēāļ18600
āļāļĢāļ°āđāļ āļāļāļēāļĢāļĢāļąāļāļĐāļēāļāļ§āļēāļĄāļāļĨāļāļāļ āļąāļĒOrdinary Share
āļŠāļīāđāļāļāļĩāļāļāļāļĢāļ°āļĄāļēāļJun 23
āļāļĩāđāļāļĒāļđāđ251 Ballardvale St
āđāļĄāļ·āļāļWILMINGTON
āļāļĨāļēāļāļŦāļĨāļąāļāļāļĢāļąāļāļĒāđNASDAQ OMX NASDAQ Basic NYSE
āļāļĢāļ°āđāļāļĻUnited States of America
āļĢāļŦāļąāļŠāđāļāļĢāļĐāļāļĩāļĒāđ01887
āđāļāļĢāļĻāļąāļāļāđ17812226000
āđāļ§āđāļāđāļāļāđhttps://www.criver.com/
āļŠāļąāļāļĨāļąāļāļĐāļāđāļĒāđāļāļāļāļāļŦāļļāđāļCRL
āļ§āļąāļāļāļĩāđāđāļŠāļāļāļāļēāļĒāļāļĢāļąāđāļāđāļĢāļJun 23, 2000
āļāļĩāļāļĩāđāļFoster (James C)
Mr. James C. Foster
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
Ms. Birgit Girshick
Chief Operating Officer, Corporate Executive Vice President
Chief Operating Officer, Corporate Executive Vice President
Ms. Victoria L. (Vicky) Creamer
Ms. Victoria L. (Vicky) Creamer
Corporate Executive Vice President, Chief People Officer
Corporate Executive Vice President, Chief People Officer
Ms. Shannon M. Parisotto
Corporate Executive Vice President - Discovery and Safety Assessment
Management
Corporate Executive Vice President - Discovery and Safety Assessment
Management
Mr. Joseph W. LaPlume
Corporate Executive Vice President - Corporate Development and Strategy
Corporate Executive Vice President - Corporate Development and Strategy
Ms. Virginia M. (Gina) Wilson, CPA
Ms. Virginia M. (Gina) Wilson, CPA
Independent Director
Dr. Nancy C. Andrews, M.D., Ph.D.
Dr. Nancy C. Andrews, M.D., Ph.D.
Independent Director
Ms. Reshema Kemps-Polanco
Ms. Reshema Kemps-Polanco
Independent Director
Dr. Craig B. Thompson, M.D.
Dr. Craig B. Thompson, M.D.
Independent Director
Mr. Abraham N. (Abe) Ceesay
Mr. Abraham N. (Abe) Ceesay
Independent Director
āļāļđāđāļāļīāđāļĄāđāļāļīāļĄ
Mr. James C. Foster
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
Ms. Birgit Girshick
Chief Operating Officer, Corporate Executive Vice President
Chief Operating Officer, Corporate Executive Vice President
Ms. Victoria L. (Vicky) Creamer
Ms. Victoria L. (Vicky) Creamer
Corporate Executive Vice President, Chief People Officer
Corporate Executive Vice President, Chief People Officer
Ms. Shannon M. Parisotto
Corporate Executive Vice President - Discovery and Safety Assessment
Management
Corporate Executive Vice President - Discovery and Safety Assessment
Management
Mr. Joseph W. LaPlume
Corporate Executive Vice President - Corporate Development and Strategy
Corporate Executive Vice President - Corporate Development and Strategy
Ms. Virginia M. (Gina) Wilson, CPA
Ms. Virginia M. (Gina) Wilson, CPA
Independent Director
Invesco S&P 500 Equal Weight Health Care ETF
Schwab Ariel Opportunities ETF
iShares Health Innovation Active ETF
First Trust NASDAQ Pharmaceuticals ETF
ROBO Global Healthcare Technology & Innovation ETF
Franklin Genomic Advancements ETF
Invesco S&P 500 High Beta ETF
Pacer Lunt Large Cap Alternator ETF
āļāļđāđāļāļīāđāļĄāđāļāļīāļĄ
Invesco S&P 500 Equal Weight Health Care ETF
āļŠāļąāļāļŠāđāļ§āļ1.92%
Schwab Ariel Opportunities ETF
āļŠāļąāļāļŠāđāļ§āļ1.82%
iShares Health Innovation Active ETF
āļŠāļąāļāļŠāđāļ§āļ1.74%
First Trust NASDAQ Pharmaceuticals ETF
āļŠāļąāļāļŠāđāļ§āļ1.71%
ROBO Global Healthcare Technology & Innovation ETF
āļŠāļąāļāļŠāđāļ§āļ1.69%
VanEck Biotech ETF
āļŠāļąāļāļŠāđāļ§āļ1.44%
Franklin Genomic Advancements ETF
āļŠāļąāļāļŠāđāļ§āļ1.42%
WisdomTree US Value Fund
āļŠāļąāļāļŠāđāļ§āļ1.15%
Invesco S&P 500 High Beta ETF
āļŠāļąāļāļŠāđāļ§āļ1.14%
Pacer Lunt Large Cap Alternator ETF
āļŠāļąāļāļŠāđāļ§āļ0.97%
āļĄāļĩāļāļēāļĢāļāđāļēāļĒāđāļāļīāļāļāļąāļāļāļĨāđāļāđāļāļāļģāļāļ§āļāļĢāļ§āļĄ
0.00
USD āđāļāļāđāļ§āļ 5 āļāļĩāļāļĩāđāļāđāļēāļāļĄāļē

āđāļĄāđāļĄāļĩāļāđāļāļĄāļđāļĨ